【摘要】 作者在建立鼻咽癌前期病变模型的基础上,研究中药复方抗癌Ⅱ片、抗癌Ⅲ片,维胺酯(RI)等对大鼠鼻腔上皮癌前病变的抑制作用:给予20 mg/kg或40 mg/kg二亚硝基哌嗪(DNP),全部动物鼻腔粘膜发生不典型增生。RI治疗组癌变率由对照组100％下降至61.5％和76.5％,预防组癌变率由对照组85.7％下降至38.4％(P<0.01);抗癌Ⅱ片、抗癌Ⅱ片与RI的联合使用预防癌变,癌变率由对照组60％分别下降至36.5％和20.1％(P<0.05);抗癌Ⅱ片.抗癌Ⅲ片治疗癌变,癌变率由对照组60％分别下降至24.1％和31.4％(P<0.05)。更多还原

【Abstract】 Experimental prevention and treatment of precancerous lesions and cancer of nasoca-vity and nasopharynx have not been report in the literature. This paper reports the inhibitory effect of the Chinese Herbs Complex, anticancer Ⅱ and anticancer Ⅲ), and the reti-noids, N-(4-ethoxycarbophenyl) retinamide (R Ⅰ ) and the combination of anticancer Ⅱ plus R Ⅰ on the carcinogenesis of the epithelia of nasocavity in rats. The results showed that in precancerous lesions, dysplasia occurred in all animals at doses of 20 or 40 mg/ kg body weight of dinitrosopiperazine (DNP) in the control group. In the studies of the treated group, in which R Ⅰ was given after the last dose of DNP, the percentage of precancerous lesions that developed into cancer decreased from 100% in the control group to 61.5% and 76.5% in the treated groups.If RⅠ was given before the DNP, i. e. the prevention group, the incidence decreased from 85.7% in the control group to 38.4% in the prevention group. The anticancer Ⅱ, Ⅲ and the combination of anticancer Ⅱ with RⅠ had significant inhibitory effects on the carcinogenesis (P<0.05). The malignant change rate of the control group was 60%; while it decreased to 36.5% in the anticancer Ⅱ prevention group; 24.1% in the anticancer Ⅱ treated group; 31.4% in the anticancer Ⅲ treated group; and 29.1% in the combination group. But only mild decreases were observed in the anticancer Ⅲ prevention group (46.0%) and asparagus group (40.0%) (P> 0.05). These studies showed that by using anticancer Ⅱ with or without the combination of R Ⅰ is a good way to decrease the malignant changes in the nasopharynx and nasocavi-ty of rats. As the anticancer Ⅱ has no side effect, it can be used in humans, especially in the high incidence area of nasopharyngeal carcinoma, to decrease the incidence rate of nasopharyngeal cancer.更多还原